It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient ...

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to ...

Recursion (NASDAQ:RXRX) just laid out a roadmap that balances science and cash, and it looks promising. CEO Christopher ...

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating ...

GAAP revenue surpassed estimates by 24.9% in Q2 2025, driven by milestone payments, including $7 million from Sanofi. Research and development expenses rose 74.0% year-over-year, reflecting higher ...

(RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake ...

In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach to drug discovery driven by AI and ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a ...